Galena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim Chief Executive Officer
February 21 2017 - 4:10PM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
developing hematology and oncology therapeutics that address unmet
medical needs, today announced that the Company’s Board of
Directors appointed Stephen F. Ghiglieri as Interim Chief Executive
Officer, effective today. Mr. Ghiglieri will also continue to
serve as the Company’s Chief Financial Officer.
“On behalf of the entire Board of Directors, we are pleased to
appoint Stephen as our Interim CEO,” said, Sanford J. Hillsberg,
Galena’s Chairman of the Board of Directors. “We believe his prior
public company experience and oversight will prove valuable to
Galena as we evaluate strategic alternatives for the company
focused on maximizing stockholder value.”
“Over the course of my career, I have been involved with various
companies that have gone through transitions and believe that my
experience will be beneficial to all of our stakeholders as we seek
an optimal outcome for Galena. I look forward to working with our
Board of Directors and management team to ensure the company
continues to execute as we identify opportunities to enhance our
value,” added Mr. Ghiglieri.
Mr. Ghiglieri, joined Galena Biopharma in November 2016 after
previously consulting for the company. He has more than 25
years in senior level finance and operational roles at both
biotechnology and technology companies. Prior to Galena, Mr.
Ghiglieri served as CFO of MedData Inc., a private equity backed
healthcare services company that was sold to Mednax, a publicly
traded national medical group. Previously, he spent nearly 10 years
at NeurogesX, ending his tenure as the Company’s Executive Vice
President, Chief Operating Officer and CFO. Prior to that he served
as the CFO of Hansen Medical, Inc., a medical device company. He
also held senior level finance positions at two other healthcare
companies: Oacis Healthcare Systems, Inc., and Oclassen
Pharmaceuticals, Inc. Additionally, he was the CFO and
Corporate Secretary for two technology software companies: Avolent,
Inc., and Andromedia, Inc. Mr. Ghiglieri began his career as an
audit manager of PricewaterhouseCoopers, LLP. He received a
Bachelor of Science in Business Administration from California
State University, Hayward, where he graduated Magna Cum Laude. Mr.
Ghiglieri is also a Certified Public Accountant (inactive).
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company developing
hematology and oncology therapeutics that address unmet medical
needs. Galena’s pipeline consists of multiple mid-to-late-stage
clinical assets led by its hematology asset, GALE-401, and its
novel cancer immunotherapy programs including NeuVax™
(nelipepimut-S) and GALE-301/GALE-302. For more information, visit
www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the progress of the strategic alternatives
evaluation, development of Galena’s product candidates,
patient enrollment in our clinical trials, as well as other
statements related to the progress and timing of our development
activities, Galena’s current and prospective financial condition,
liquidity and access to capital, present or future licensing,
collaborative or financing arrangements, expected outcomes with
regulatory agencies, and projected market opportunities for product
candidates or that otherwise relate to future periods. These
forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including those identified under
“Risk Factors” in Galena’s Annual Report on Form 10-K for the year
ended December 31, 2015, most recent Quarterly Reports on Form
10-Q, current reports on Form 8-K and and on the prospectus
supplement to the registration statement related to the public
offering filed with the SEC. Actual results may differ materially
from those contemplated by these forward-looking statements. Galena
does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or
circumstances that occur after the date of this press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Source: Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024